EHA 2022: Journaal AML

Het jaarlijkse congres van de European Hematology Association vond dit jaar in plaats in Wenen. In dit EHA-journaal is prof. dr. Gerwin Huls te gast om samen met Inge Diepman het belangrijkste congresnieuws op het gebied van AML door te nemen.

Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts:

• Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML
• 10-day decitabine vs. conventional chemotherapy ('3+7') followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase iii study of the EORTC Leukemia Group, GINEMA, CELG, and GMDS-SG
• A randomised comparison of CPX-351 and FLAG-IDA in high risk acute myeloid leukaemia. results from the NCRI AML19 trial
• Clinical implications of secondary-AML type mutations in patients with de novo acute myeloid leukemia
• NPM1 mutated AML: impact of co-mutational patterns - results of the European HARMONY Alliance
• Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: phase 1b results
• Quizartinib with decitabine and venetoclax (triplet) is active in patients with FLT3-ITD mutated acute myeloid leukemia - a phase I/II study
• TAKEAIM Leukemia- a phase 1/2a study of the IRAK4 inhibitor emavusertib (CA-4948) as monotherapy or in combination with azacitidine or venetoclax in relapsed/refractory AML or MDS
• Off-the-shelf CD33 CAR-NK cell therapy for relapse/refractory AML: first-in-human, phase I trial

Bekijk hier het volledige overzicht van onze EHA 2022 journaals en interviews.